ASX:ANR Anatara Lifesciences (ANR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Anatara Lifesciences Stock (ASX:ANR) Get Anatara Lifesciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,950 shsAverage VolumeN/AMarket CapitalizationA$11.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia. Read More Receive ANR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anatara Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANR Stock News HeadlinesAnatara Lifesciences Addresses ASX Query Amid Market ActivitySeptember 4, 2025 | tipranks.comAnatara Lifesciences Reports Increased Loss Amidst Continued OperationsAugust 13, 2025 | tipranks.comThe End of Elon Musk…?Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.September 16 at 2:00 AM | Brownstone Research (Ad)Anatara Lifesciences Converts Performance Rights to SharesAugust 3, 2025 | tipranks.comAnatara Lifesciences Secures R&D Tax Incentive to Propel Anti-Obesity ResearchJuly 27, 2025 | tipranks.comAnatara Lifesciences Sees Change in Substantial Shareholder InterestsJuly 1, 2025 | tipranks.comAnatara Lifesciences Secures Hong Kong Patent for GaRP ProductMay 18, 2025 | tipranks.comAnatara Lifesciences Reports GaRP-IBS Trial Results and Future DirectionsApril 16, 2025 | tipranks.comSee More Headlines ANR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Anatara Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anatara Lifesciences investors own include Woodside Petroleum (WPL), Temple & Webster Group (TPW), Brompton Oil Split (OSP), Eagle Materials (EXP), BHP Group (BHP) and Ameriprise Financial (AMP). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:ANR CIKN/A Webwww.anataralifesciences.com Phone61 7 3394 8202FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$1.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-110.25% Return on Assets-59.01% Debt Debt-to-Equity RatioN/A Current Ratio5.49 Quick Ratio4.69 Sales & Book Value Annual SalesA$1.25 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.33 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares192,890,000Free FloatN/AMarket CapA$11.74 million OptionableNot Optionable Beta0.72 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (ASX:ANR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anatara Lifesciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Anatara Lifesciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
